Objective The indications for endoscopic submucosal dissection (ESD) in patients with early gastric cancer (EGC) have been expanded. However, the long-term outcomes of ESD remain unclear. We retrospectively investigated the long-term outcomes of ESD in patients with EGC. Methods We retrospectively studied patients with EGC who underwent ESD at 11 institutions between January 2003 and December 2010. A total of 6456 patients (7979 lesions) who met the absolute indications for ESD and 4202 patients (5781 lesions) who met the expanded indications for ESD were studied. Clinicopathological features, clinical course, and outcomes were studied in 67 patients in whom local recurrence or metastatic recurrence was diagnosed as of March 31, 2014. The median follow-up period was 56 months. Results Local recurrence was diagnosed in 14 patients (0.22%) who met the absolute indications and 53 patients (1.26%) who met the expanded indications. The rate of local recurrence was significantly higher in patients with expanded-indication lesions (p \ 0.05). As additional treatment for recurrence, most patients received endoscopic treatment. Metastatic recurrence did not develop in any patient with absolute-indication lesions, but was diagnosed in 6 patients (0.14%) with expanded-indication lesions This manuscript is a modified version of that published in the Japanese journal Stomach and Intestine 2014;49(11):1601-1608 in the Japanese language, entitled ''Clinicopathological features, progress, and prognosis in the cases of local recurrence and metastatic recurrence following endoscopic submucosal dissection for gastric cancer: a multi-institutional joint study.'' Because of its important clinical implications we submitted the present English-language version of the manuscript to Gastric Cancer to reach a broader audience of readers. 
Abstract
Objective The indications for endoscopic submucosal dissection (ESD) in patients with early gastric cancer (EGC) have been expanded. However, the long-term outcomes of ESD remain unclear. We retrospectively investigated the long-term outcomes of ESD in patients with EGC.
Methods We retrospectively studied patients with EGC who underwent ESD at 11 institutions between January 2003 and December 2010. A total of 6456 patients (7979 lesions) who met the absolute indications for ESD and 4202 patients (5781 lesions) who met the expanded indications for ESD were studied. Clinicopathological features, clinical course, and outcomes were studied in 67 patients in whom local recurrence or metastatic recurrence was diagnosed as of March 31, 2014. The median follow-up period was 56 months.
Results Local recurrence was diagnosed in 14 patients (0.22%) who met the absolute indications and 53 patients (1.26%) who met the expanded indications. The rate of local recurrence was significantly higher in patients with expanded-indication lesions (p \ 0.05). As additional treatment for recurrence, most patients received endoscopic treatment. Metastatic recurrence did not develop in any patient with absolute-indication lesions, but was diagnosed in 6 patients (0.14%) with expanded-indication lesions
This manuscript is a modified version of that published in the Japanese journal Stomach and Intestine 2014;49 (11) :1601-1608 in the Japanese language, entitled ''Clinicopathological features, progress, and prognosis in the cases of local recurrence and metastatic recurrence following endoscopic submucosal dissection for gastric cancer: a multi-institutional joint study.'' Because of its important clinical implications we submitted the present English-language version of the manuscript to Gastric Cancer to reach a broader audience of readers.
Introduction
More than 10 years have elapsed since the development of endoscopic dissection (ESD). Improvements in instruments and devices and progress in techniques have led to the rapid dissemination of ESD in clinical practice. ESD has enabled the en bloc resection of lesions that previously had to be resected in a piecemeal fashion by conventional endoscopic mucosal resection (EMR) [1] . One of the most important features of ESD is that accurate pathological evaluation is possible. Clinical expansion of the indications for ESD has been attempted on the basis of the findings of Gotoda et al. [2] . However, the long-term outcomes of lesions meeting the expanded indications for ESD remain unclear [3, 4] . In the present multicenter collaborative study, we retrospectively evaluated the long-term outcomes of lesions that met the absolute indications (absolute-indication lesions) or the expanded indications (expanded-indication lesions) for ESD in patients with early gastric cancer (EGC). The study protocol and analysis were approved by the ethics committees of each participating hospital.
Subjects
Among patients with EGC (absolute-indication lesions or expanded-indication lesions) who underwent ESD from January 2003 through December 2010, we studied patients who had local recurrence or metastatic recurrence as of March 31, 2014 (i.e., patients who were followed up for at least 3 years).
Methods
The study protocol was prepared, and the co-investigators requested the ethics committee in each hospital to review the study protocol. The study protocol was approved by all hospitals. Satoshi Tanabe was the chief investigator, and Kenji Ishido was in charge of the study secretariat office, which sent the patient case report forms to the co-investigators. The responsible co-investigator at each participating hospital completed the case report forms and sent them to the study secretariat office, which then compiled and analyzed the study data. Statistical analysis was performed with chi-square tests, and P values of less than 0.05 were considered to indicate statistical significance.
Study variables
The following variables were studied: age at the time of treatment, sex, concurrent underlying diseases, conditions defining indications (absolute-indication lesion or expanded-indication lesion), macroscopic type, presence or absence of ulcer, tumor location, preoperative invasion depth (mucosa, M or submucosa, SM), pathological invasion depth (mucosa, M or first layer of the submucosa, SM1), greatest tumor diameter, main histological type, undifferentiated mixed-type cancer (differentiated-typepredominant or undifferentiated-type-predominant), lymphovascular invasion (lymph nodes, ly or blood vessels, v), resection margins (horizontal margin, HM and vertical margin, VM), additional treatment after ESD, date of confirming local residual tumor or recurrence, treatment for local residual tumor or recurrence, presence or absence of metastatic recurrence, treatment for metastatic recurrence, outcomes, and the cause of death (death from gastric cancer, death from other diseases). Lymphatic involvement was evaluated by D2-40 immunostaining.
Criteria defining absolute-indication lesions and expanded-indication lesions according to the Japanese Gastric Cancer Association (JGCA) state absolute-indication criteria for the endoscopic treatment of differentiated mucosal cancer include tumors less than 2 cm in diameter, without ulceration [5] . On the other hand, the expanded-indication criteria proposed by Gotoda et al. [2] recommend endoscopic resection for the management of differentiated mucosal cancer regardless of size in the absence of ulceration or tumors less than 3 cm in diameter in the presence of ulceration. In addition, we included lesions with minute submucosal invasion (SM1: invasion depth 500 lm below the muscularis mucosae) that were less than 30 mm in diameter.
Results
Subjects (Table 1) The study group comprised patients with EGC who underwent ESD in the 11 participating hospitals from January 2003 through December 2010. A total of 6456 S46 S. Tanabe et al.
patients with 7979 absolute-indication lesions and 4202 patients with 5781 expanded-indication lesions were studied. The median follow-up was 56 months (range, 39-76 months). The overall capture rate was 76.0%. Outcomes were confirmed by telephone or letter in about 50% of patients with each type of lesion.
Local recurrence rates (Table 1) Local recurrence occurred in 14 patients (0.22%) with absolute-indication lesions and 53 patients (1.26%) with expanded-indication lesions. The rate of local recurrence was significantly higher in patients with expanded-indication lesions (p \ 0.05).
Clinicopathological features of local recurrence (Table 2) The sites of local residual tumor or recurrence were approximately equally distributed in the upper, middle, and lower thirds of the stomach for both absolute-indication lesions and expanded-indication lesions. Macroscopically, the majority of absolute-indication lesions and expandedindication lesions were flat or depressed. The median tumor diameter was significantly greater for expanded-indication lesions (30 mm) than for absolute-indication lesions (7 mm). The depth of tumor invasion was intramucosal (M) in 49 of the 53 patients with expanded-indication lesions. The histological type was undifferentiated mixedtype cancer in 1 (7%) of the 14 patients with local recurrence of absolute-indication lesions and 9 (17%) of the 53 patients with local recurrence of expanded-indication lesions (differentiated-type predominant in 7 patients and undifferentiated-type predominant in 2 patients). The horizontal margin was positive in 7 (50%) patients with absolute-indication lesions and 30 (57%) patients with expanded-indication lesions. The vertical margin was positive in no patient with absolute-indication lesions and in 1 patient with expanded-indication lesions. The vertical margin could not be evaluated in 5 patients because of heat denaturation. The median time to the development of local recurrence was significantly shorter in patients with expanded-indication lesions (8 months) than in those with absolute-indication lesions (15 months).
Courses and outcomes of patients with local recurrence
Absolute-indication lesions ( Fig. 1) Additional treatment for the 14 patients who had local recurrence of absolute-indication lesions comprised endoscopic treatment in 12 patients and surgery in 1 patient. The other patient was followed up with no further treatment because of advanced age. The endoscopic treatment procedure was ESD in 11 patients and argon plasma coagulation (APC) in 1. At the time of this writing, all these patients are still alive with no subsequent recurrence. The patient who was followed up without additional treatment died of another disease.
Expanded-indication lesions (Fig. 2)
The clinical courses of the 53 patients who had local recurrence of expanded-indication lesions are shown in recurrence was lymph nodes in five patients and the lung in one. As additional treatment, two patients underwent surgery and three received chemotherapy. The remaining patient was followed up with no further treatment. At the time of this writing, three of the six patients are still alive, and three have died of gastric cancer.
Discussion
The advent of ESD has led to substantial progress in endoscopic treatment for EGC. The indication range of ESD is now being broadened from absolute-indication lesions to include expanded-indication lesions. The longterm outcomes of ESD in patients with absolute-indication lesions have been reported to be equivalent to those of curative surgery [6] . However, a consensus has yet to be reached concerning the long-term outcomes of ESD in patients with expanded-indication lesions [3, 4, 7] . In clinical practice, treatment is performed after patients are informed that the indication range of ESD is currently being expanded on a clinical research basis. Local recurrence and metastatic recurrence have different underlying mechanisms. Local recurrence can occur when curative (R0) resection is not achieved at lateral or deep margins. In contrast, metastatic recurrence is associated with the presence of risk factors such as submucosal microinvasion and lymphovascular invasion even after R0 resection. The rate of locoregional recurrence has been reported to range from 1.9% to 6.6% for conventional EMR [8] [9] [10] [11] , as compared with only 0.2% to 3.7% for ESD with en bloc resection [12] [13] [14] . In our previous singlecenter retrospective study [12] , the rate of local recurrence of absolute-indication lesions was significantly lower in patients who underwent ESD (0%) than in those who underwent EMR (2.9%). In patients with expanded-indication lesions, the rate of local recurrence was also significantly lower for ESD (0.6%) than for EMR (12.5%). These findings showed that the local recurrence rate of expanded-indication lesions was particularly high after EMR and clearly demonstrated the value of en bloc resection by ESD.
In the present multicenter collaborative study, we analyzed local recurrence and metastatic recurrence in a series of more than 10,000 patients with EGC who underwent ESD. The local recurrence rate was significantly higher for expanded-indication lesions than for absolute-indication lesions.
As for the clinicopathological characteristics associated with local recurrence of expanded-indication lesions, the most common macroscopic type of tumor was flat or depressed type, which was present in 75.5% of the patients who underwent noncurative resection. Several groups of investigators have reported that incomplete resection and tumor-positive horizontal resection margins are risk factors for local recurrence [13] [14] [15] [16] . Imagawa et al. [17] reported that tumor location (upper third of the stomach) and size (C2 cm) are technical factors related to incomplete resection. Takenaka et al. [13] also proposed that tumor location in the upper part of the stomach and a tumor diameter C30 mm are risk factors for local recurrence. Kakushima et al. [18] reported that a tumor diameter C30 mm, recurrent lesions, submucosal invasion, and undifferentiated cancer are risk factors for a positive horizontal resection margin. In our study, the median tumor diameter in patients who had local recurrence of expanded-indication lesions was 30 mm. Han et al. [19] studied the relationship between histological type and local recurrence and found that the local recurrence rate was significantly higher in patients with histologically mixed-type cancer (19.8%) than in those with differentiated-type cancer (1.7%) or undifferentiated-type cancer (9.8%). Their analysis indicated that histologically mixed-type cancer is associated with a higher rate of incomplete resection. Because 9 patients with local recurrence of expanded-indication lesions in our series had undifferentiated mixed-type cancer, preoperative diagnosis might have been challenging. A recent study Tub1 well differentiated adenocarcinoma, Tub2 moderately differentiated adenocarcinoma, ne not evaluated, por poorly differentiated adenocarcinoma, sig signet ring cell carcinoma has reported the usefulness of image-enhanced endoscopy and magnifying endoscopy [20] . However, these endoscopic techniques have their limitations in patients with undifferentiated mixed-type cancer [21] , and other measures, including preoperative biopsy of the surrounding region, are most likely required for an accurate diagnosis. Sekiguchi et al. [22] studied local recurrence in patients with tumor-positive horizontal margins and reported that a positive horizontal margin of 6 mm or longer is an independent risk factor for local recurrence. How to treat patients with positive horizontal margins remains a matter of debate. Various treatments are currently used on a patient-specific and hospital-specific basis. Endoscopic treatment was used to manage local recurrence in 12 (86%) of 14 patients with absolute-indication lesions, 11 of whom underwent ESD, and in 46 (87%) of 53 patients with expanded-indication lesions, 41 of whom underwent ESD. ESD has been reported to be useful for the treatment of local recurrence [23] , but it is associated with the development of fibrous scar tissue, a high level of technical difficulty, and a high risk of perforation. These problems should be addressed in future studies.
Metastatic recurrence was not found in any patient with absolute-indication lesions but developed in six patients with expanded-indication lesions (0.14%). This difference was statistically significant. Several previous studies have evaluated outcomes in patients with expanded-indication lesions and found no difference in outcomes between expanded-indication lesions and absolute-indication lesions [3, 4, 7] . All these studies were conducted in a single center and had a relatively small sample size. In our study, only a very few patients had metastatic recurrence. We believe that patients with expanded-indication lesions should be followed up according to a stricter protocol than patients with absolute-indication lesions.
The theoretical basis for expanding the indication range of ESD is as follows. In the National Cancer Center Hospital, the 5-year survival rate after surgical resection of EGC is 99% in patients with mucosal cancer and 96% in those with submucosal cancer, excluding deaths from other diseases.
Therefore, if the rate of metastasis after ESD was 1% or less for mucosal cancer and 4% or less for submucosal cancer, the outcomes of ESD were hypothesized to be equivalent to those of surgical resection. On the basis of this theoretical calculation, the rate of metastatic recurrence in our study was within expectation. As for the risk of surgery, Kikuchi et al. [24] reported that 3 (0.35%) of 851 patients with EGC died of surgery-related causes. Surgery is therefore associated with a certain risk. Given that all confirmed cases of metastatic recurrence in our study developed in patients who were evaluated to have undergone curative resection, the risk of metastatic recurrence after endoscopic treatment for expanded-indication lesions should be thoroughly explained to patients and informed consent should be obtained preoperatively, even though the risk is less than 1%. To our knowledge, this is the first multicenter study to evaluate the risk of metastatic recurrence after ESD in such a large series of patients with EGC. We therefore consider our results valuable. As for ESD for expanded-indication lesions of early gastric cancer, ulceration and submucosal invasion have been reported to be risk factors for metastatic recurrence [2] . Undifferentiated mixed-type cancer has been reported to be associated with higher biological malignancy than pure differentiated-type cancer, potentially leading to high rates of lymphatic invasion and lymph node metastasis [25] . Takizawa et al. [26] studied intramucosal gastric cancer in patients who underwent surgery and reported that 13.2% of patients had mixed predominantly differentiated cancer (MD) and 10.2% had mixed predominantly undifferentiated cancer (MU). The rate of lymph node metastasis was high in patients with MU (24%). In contrast, none of the patients with MD had lymph node metastasis. In our study, three of the six patients with metastatic recurrence had undifferentiated mixed-type gastric cancer. The management of such cases, including preoperative diagnosis, is an issue for future studies.
Our study had several important limitations. It had a retrospective design and mainly evaluated patients who had recurrence. There was no matching between patients with absolute-indication lesions and those with expanded-indication lesions, and the ESD technique and follow-up protocol were not standardized. The results of a prospective clinical study by the Japan Clinical Oncology Group (JCOG0607 study) [27] are awaited.
In conclusion, metastatic recurrence was not observed in any patient with absolute-indication lesions but did develop in a very small number of patients with expanded-indication lesions. These results are considered equivalent to those of surgical therapy. ESD for expanded-indication lesions of early gastric cancer is associated with an extremely low rate of metastatic recurrence on long-term follow-up and is thus considered an appropriate treatment. However, fully informed consent about the risk of metastatic recurrence should be obtained before ESD, and close postoperative follow-up is essential.
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